1998
DOI: 10.1016/s0194-5998(98)70274-8
|View full text |Cite
|
Sign up to set email alerts
|

Preliminary Results of the Use of Indole‐3‐Carbinol for Recurrent Respiratory Papillomatosis

Abstract: The preliminary results of treating recurrent respiratory papillomatosis with indole-3-carbinol holds promise. Longer follow-up of this patient group and a blinded, controlled trial are required. We conclude that indole-3-carbinol appears to be safe and well tolerated and may be an efficacious treatment for recurrent respiratory papillomatosis.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
83
0
2

Year Published

2002
2002
2014
2014

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 138 publications
(86 citation statements)
references
References 18 publications
1
83
0
2
Order By: Relevance
“…In this regard, increased production of 2-hydroxyestradiol relative to 4-hydroxyestradiol and 16α-hydroxyestrone has been observed after exposure to indole 3-carbinol, a dietary micronutrient and AHR proligand. This finding is of potential clinical importance for cancer, since indole carbinols, that bind AHR as acid condensation products, are in clinical trials as cancer chemoprotective agents (Gillner et al, 1985;Malloy et al, 1997;Michnovicz et al, 1997;Telang et al, 1997;Rosen et al, 1998;Yuan et al, 1999;Bell et al, 2000)(reviewed by (Shertzer et al, 2000)). …”
Section: Effects Of Gender and Sex Hormones In The Tcdd Dose-responsementioning
confidence: 99%
“…In this regard, increased production of 2-hydroxyestradiol relative to 4-hydroxyestradiol and 16α-hydroxyestrone has been observed after exposure to indole 3-carbinol, a dietary micronutrient and AHR proligand. This finding is of potential clinical importance for cancer, since indole carbinols, that bind AHR as acid condensation products, are in clinical trials as cancer chemoprotective agents (Gillner et al, 1985;Malloy et al, 1997;Michnovicz et al, 1997;Telang et al, 1997;Rosen et al, 1998;Yuan et al, 1999;Bell et al, 2000)(reviewed by (Shertzer et al, 2000)). …”
Section: Effects Of Gender and Sex Hormones In The Tcdd Dose-responsementioning
confidence: 99%
“…I3C, which is generated by glycoside-hydrolyzing enzymes when plant cells are disrupted by processing, cooking or mastication, possesses chemopreventive properties against chemically induced tumors in rodents at a variety of sites. [11][12][13][14] Clinical pilot studies of I3C have been conducted in patients with recurrent respiratory papillomatosis 15 and cervical intraepithelial neoplasia. 16 There has also been a dose-finding study to prepare for its evaluation as a breast cancer preventive agent.…”
mentioning
confidence: 99%
“…I3C and DIM are said to be the most popular adjunct therapies for this disorder because of their effectiveness and low level of toxicity (Auborn, 2002;Wiatrak, 2003). RRP is caused by certain types of human papilloma viruses (Coll et al, 1997;Rosen et al, 1998), and a hallmark of this disease is the tendency of the papillomas to recur after surgical removal (Gissmann et al, 1982;Kashima et al, 1996). One report indicated that most patients (55.4%) responded to the treatment of I3C/DIM by slowing down the recurrence rate, and recurrence of the disease was completely inhibited in 19% of patients (Yuan et al, 1999).…”
Section: Discussionmentioning
confidence: 99%